Retatrutide for managing overweight and obesity [ID6644] Awaiting Development
Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review
In clinical studies, people on semaglutide lost about 12% of their body weight compared to only around 5% with liraglutide
caution and clinical monitoring are appropriate People taking insulin or insulin secretagogues (such as sulphonylureas), where the risk of hypoglycaemia may be increased, and dose adjustment of the concomitant agent may be needed Those with active or unstable diabetic retinopathy , given the potential for transient worsening with rapid glycaemic improvement People taking oral medicines with a narrow therapeutic index , where delayed gastric emptying could affect drug absorption Regarding medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN2): animal studies with GLP-1 receptor agonists have shown thyroid C-cell changes, and some regulatory authorities have issued precautionary warnings
Clinical trial enrollment
Bradley also added, There is nothing new about phentermine which was first approved in 1959
